Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection

Clinical Transplantation

Volumn 20, Issue 6, 2006, Pages 689-694

  Lee, Timothy C ^a   Goss, John A ^a   Rooney, Cliona M ^b   Heslop, Helen E ^b   Barshes, Neal R ^a   Caldwell, Yvette M ^b   Gee, Adrian P ^b   Scott, Jaymee D ^a   Savoldo, Barbara ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Epstein Barr virus; Immunosuppression; Pediatric liver transplant

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD3 ANTIGEN; PHYTOHEMAGGLUTININ; PREDNISONE; RITUXIMAB; STEROID; TSUKUBAENOLIDE; VIRUS DNA;

ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOASSAY; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD;

ADENOSINE TRIPHOSPHATE; ANTIGENS, CD3; BIOPSY; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; LIVER TRANSPLANTATION; LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 33750826409     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00537.x     Document Type: Article

References (17)

1. + T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation. J Infect Dis 2004: 190: 1596.
2. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001: 1: 103.
3. Guthery SL, Heubi JE, Bucuvalas JC et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003: 75: 987.
4. Duvoux C, Pageaux GP, Vanlemmens C et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: An analysis of 480 patients. Transplantation 2002: 74: 1103.
5. + T cells specific for EBV in healthy virus carriers. J Immunol 1999: 162: 1827.
6. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998: 187: 1395.
7. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998: 92: 1549.
8. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996: 2: 551.
9. Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005: 5: 566.
10. Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001: 97: 1165.
11. Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004: 103: 3979.
12. Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005: 5: 2222.
13. Rovira P, Mascarell L, Truffa-Bachi P. The impact of immune suppressive drugs on the analysis of T cell activation. Curr Med Chem 2000: 7: 673.
14. Ahmed M, Venkataraman R, Logar AJ et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit 2001: 23: 354.
15. Kowalski R, Post D, Schneider MC et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003: 17: 77.
16. Smets F, Latinne D, Bazin H et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002: 73: 1603.
17. Hooper E, Hawkins DM, Kowalski RJ et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant 2005: 19: 834.